GBI Research

Report: Antibiotics pipeline boasts 741 products, first-in-class development remains low

Wednesday, March 25, 2015 03:17 PM

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, said business intelligence provider GBI Research, a New York-based provider of business intelligence reports.

More... »

Quest Diagnostics

Report: Parkinson’s treatment pipeline targeting functional processes over genes

Thursday, December 4, 2014 12:35 PM

The Parkinson’s disease (PD) treatment pipeline is characterized by a high degree of innovation and diverse molecular targets, with 37% of 302 products holding first-in-class status, according to New York-based business intelligence provider GBI Research.

More... »


Report: AML treatment market to witness modest growth by 2020

Wednesday, November 26, 2014 11:53 AM

The value of the global acute myeloid leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, according to New York-based business intelligence provider GBI Research.

More... »

South and Central America API market closing gap on northern neighbors

Wednesday, August 22, 2012 09:57 AM
The active pharmaceutical ingredients (API) market in the Americas was worth a staggering $46 billion in 2011, with North America accounting for over 88% of it. But due to rapidly expanding economies and improvements in healthcare, South and Central America (SCA) are set to take a more substantial chunk in the future, according to a new report from GBI Research, a pharmaceutical industry analyst.

More... »

Standardized trial endpoints to help health authorities tackle respiratory diseases

Wednesday, June 20, 2012 12:16 PM

Science is standardizing the way respiratory health is measured, helping to judge the effectiveness of drug treatments better than ever, according to a new report by healthcare experts GBI Research.

More... »

Report: Orphan drug market on the rise

Thursday, May 24, 2012 09:00 AM

GBI Research, a pharmaceutical market expert, has released its report "Orphan Disease Therapeutics Market to 2018: Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation,” which provides insights into the orphan disease therapeutics market until 2018.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs